Investor Centre

Investor Fact Sheet

Corporate Profile

Acrux (ASXAustralian Securities Exchange: ACR) develops and commercialises pharmaceutical products for global markets, using innovative technology to administer proven medicines through the skin. Its unique products are fast-drying, invisible sprays and liquids which are applied to the skin, delivering the medicine transdermally into the bloodstream. Each product is designed to be preferred by patients over current therapies. The delivery technology was originally invented by scientists at Monash University and is covered by broad, well-differentiated issued patents.

Acrux earns revenue from its products through licensees in pharmaceutical markets around the world. Acrux reported a maiden profit in 2010 and paid a special dividend to shareholders of 60 cents per share ($100 million) in 2011, followed by a first regular dividend in 2012. Acrux received two 2010 Governor of Victoria Export Awards, including the Victorian Export Award for Innovation Excellence.

In March 2010, Acrux signed the largest single product licensing deal in the history of Australian biotechnology for Axiron®, a treatment for hypogondism (testosterone deficiency in men). In November 2010, Axiron was approved by the US Food and Drug Administration (FDAFood and Drug Administration) for marketing in the United States. Acrux executed and funded the entire development of Axiron, through to FDA approval. Acrux’s worldwide licensee Eli Lilly launched Axiron into a billion dollar US market in April 2011, with potential distribution into another 142 countries.

Acrux has further products approved for marketing in the United States and Europe, in registration for the United States, Canada, South Africa and South Korea, and at earlier stages of development.

Acrux Limited is a Pooled Development Fund, registered under the Pooled Development Fund Act 1992. Shareholders are entitled to concessionary tax treatment in Australia for income and capital gains derived in connection with their shareholding.

Last Code Change Open High Low Volume Updated
ACR
$0.29
Open 0.30
High 0.30
Low 0.28
Volume 718,423
-0.01 (-1.7%)
As at 4:00PM 23/02/2017

Acrux Limited

103-113 Stanley Street
West Melbourne VIC 3003
Australia

Telephone: +61 3 8379 0100
Facsimile: +61 3 8379 0101

Investor Relations

Sharon Papworth
Chief Financial Officer and Company Secretary

Nina Webster
Commercial Director

Email: investor@acrux.com.au
Phone: +61 3 8379 0100

Business Development

Nina Webster
Commercial Director

Email: bd@acrux.com.au
Phone: +61 3 8379 0100

Share Registry

Link Market Services
Level 1, 333 Collins Street
MELBOURNE VIC 3000
Locked Bag A14, Sydney South, NSW 1235

Toll-free: 1300 554 474 (Australia only)
International: +61 1300 554 474
Facsimile: (02) 9287 0303
Facsimile: (02) 9287 0309 (for proxy voting)

Email: registrars@linkmarketservices.com.au
Web: www.linkmarketservices.com.au

Board of Directors

Ross Dobinson , BBus Management
Non-Executive Chairman

Bruce Parncutt , BSc, MBA
Non-Executive Director

Tim Oldham , BSc(Hons), LLB(Hons), PhD
Non-Executive Director

Michael Kotsanis , BSc, MBus
Chief Executive Officer & Managing Director

Management Team

Michael Kotsanis , BSc, MBus
Chief Executive Officer & Managing Director

Sharon Papworth , B.Com, CA
Chief Financial Officer & Company Secretary

Nina Webster , Ph.D., M.IP.Law, MBA
Commercial Director

Felicia Colagrande , BSc(Hons)
Product Development and Technical Affairs Director